Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
about
Immunological effects of everolimus in patients with metastatic renal cell cancer.The effect of foxp3-overexpressing Treg cells on non-small cell lung cancer cells.IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates.Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research ReportPrognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
P2860
Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Indoleamine 2,3-dioxygenase re ...... in the tumor microenvironment.
@en
Indoleamine 2,3-dioxygenase re ...... in the tumor microenvironment.
@nl
type
label
Indoleamine 2,3-dioxygenase re ...... in the tumor microenvironment.
@en
Indoleamine 2,3-dioxygenase re ...... in the tumor microenvironment.
@nl
prefLabel
Indoleamine 2,3-dioxygenase re ...... in the tumor microenvironment.
@en
Indoleamine 2,3-dioxygenase re ...... in the tumor microenvironment.
@nl
P2093
P2860
P356
P1433
P1476
Indoleamine 2,3-dioxygenase re ...... in the tumor microenvironment
@en
P2093
Anandi Sawant
Jaroslaw Zmijewski
Jessy S Deshane
Kenneth P Hough
Selvarangan Ponnazhagan
Stefan C Grant
Victor J Thannickal
P2860
P304
75407-75424
P356
10.18632/ONCOTARGET.12249
P407
P577
2016-11-01T00:00:00Z